Richard Moro, PA
Physician Assistant · Plainfield, CTNPI 1700859006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 1,505 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,505 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$1K
- Novo Nordisk$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $13K from 52 others
What the payments were for
- Food & beverage$24,24098%
- Education$4892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,728 in reported general payments places this provider in the 95th percentile of 1,795 physician assistant providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $118,920 |
| MounjaroTirzepatide | 65 | $114,131 |
| JardianceEmpagliflozin | 102 | $106,779 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $61,008 |
| FarxigaDapagliflozin Propanediol | 51 | $57,246 |
| Nurtec OdtRimegepant Sulfate | 17 | $44,967 |
| TradjentaLinagliptin | 39 | $34,620 |
| EliquisApixaban | 37 | $33,284 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $28,901 |
| TivicayDolutegravir Sodium | 12 | $28,512 |
| RexultiBrexpiprazole | 17 | $27,081 |
| TrintellixVortioxetine Hydrobromide | 23 | $26,974 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $24,391 |
| Repatha SureclickEvolocumab | 24 | $22,085 |
| JubliaEfinaconazole | 19 | $19,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $1,345 | $152,521160 claims |
| Novo NordiskOzempic | $1,273 | $118,92088 claims |
| Lilly USA, LLCMounjaro | $744 | $114,13165 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,139 | $81,63782 claims |
| PfizerNurtec Odt, Eliquis | $793 | $78,25154 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,810 | $73,20197 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $504 | $31,93536 claims |
| GileadDescovy | $14 | $28,90113 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $408 | $27,08117 claims |
| AbbVieLinzess, Synthroid | $3,892 | $18,53846 claims |
| BayerKerendia | $900 | $16,85720 claims |
| Axsome Therapeutics, Inc.Auvelity | $623 | $16,31911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,795 physician assistant providers in Connecticut.
Other physician assistant in Plainfield
- John MackeyPlainfield$18K
- Gary SpinnerBridgeport$119K
- Jordan MarcouTrumbull$44K
- Mary ElliottGuilford$43K
- Christopher ThompsonGroton$42K
- Michael LalondeNew Haven$35K
- Kristine LaneMiddletown$30K
- Kathryn MidgleyNew Haven$28K
- Janine TedescoDarien$21K
- Marina MathewFairfield$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.